foxo4-dri senolytic human trial 2024 2025 peptide FOXO4-DRI UK FOXO4-DRI induces keloid senescent fibroblast
FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology What are the recommended dosing regimens, safety monitoring, and clinical trial considerations for senolytic agents such as dasatinib + quercetin, navitoclax, fisetin, and FOXO4DRI? Rubedo Life Sciences has reached an exciting milestone with the launch of its Phase 1 clinical trial for RLS1496, a firstinclass GPX4 modulator designed to selectively target pathologic senescent cells, a key Cellular senescence and senolytics: the path to the clinic Nature Medicine FOXO4 DRI Results: What to Expect (2026) Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link
Pay in 4 interest-free payments of $6.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



